Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Ali_Health
|
| gptkbp:acquisition |
multiple companies in the healthcare sector
|
| gptkbp:ceo |
gptkb:Deng_Yaping
|
| gptkbp:employees |
over 20,000
|
| gptkbp:focus |
gptkb:Company
generic drugs innovative drugs |
| gptkbp:founded |
gptkb:1994
|
| gptkbp:headquarters |
gptkb:Shanghai,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shanghai Pharmaceuticals
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:market_cap |
$10 billion (2020)
|
| gptkbp:partnerships |
various global pharmaceutical companies
|
| gptkbp:products |
medications
|
| gptkbp:research_and_development |
significant investment
|
| gptkbp:revenue |
$5 billion (2020)
|
| gptkbp:stock_exchange |
gptkb:Shanghai_Stock_Exchange
|
| gptkbp:subsidiary |
Shanghai Pharmaceutical Holding Co., Ltd.
|